Purpose: On August 16, 2022, the Prescribing Information for VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% was updated following a voluntary submission by Allergan, an AbbVie company, to the U.S. Food and Drug Administration (FDA). New information has now been included in the Warnings and Precautions, Postmarketing Experience, and Patient Counseling Information sections. This ASCRS Task Force was convened to develop an understanding of the data and a preliminary consensus on appropriate counseling of patients regarding risks associated with the use of VUITY. Read more in full PDF.
ASCRS Consensus Statement on VUITY | ASCRS Task Force
Leads: Douglas Rhee, MD, Cathleen McC abe, MD, Leon Herndon, MD, Rajesh Rao, MD